![](https://endpts.com/wp-content/uploads/2019/10/Dan-Skovronsky-Eli-Lilly-facebook-4.png)
Dan Skovronsky, Eli Lilly CSO (Lilly via Facebook)
Eli Lilly tees up discovery pact worth more than $1.6B with Merus for T cell-focused bispecific antibodies
Under science chief Dan Skovronsky, Eli Lilly has taken some big swings at next-gen therapies, including trying to find the next big thing in oncology …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.